Tectonic Therapeutic to Participate in March Investor Conferences
Rhea-AI Summary
Tectonic Therapeutic (NASDAQ: TECX) said management will participate in two investor conferences in March 2026: TD Cowen on March 4, 2026 in Boston and Leerink on March 11, 2026 in Miami.
Each appearance is a fireside chat with CEO Alise Reicin, MD, available via webcast and replay on the company website for ~90 days; management will also hold one-on-one meetings by request.
Positive
- None.
Negative
- None.
News Market Reaction – TECX
In the Mar 2 session, TECX declined 1.92%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.5% during that session. Argus tracked a trough of -5.3% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Board leadership change | Positive | +0.8% | Appointment of François Nader as independent director and incoming board Chair. |
| Feb 11 | KOL event announcement | Positive | +3.2% | Announcement of TX2100-focused virtual key opinion leader event with Phase 1 plans. |
| Dec 01 | Investor conferences | Neutral | -4.5% | Participation in December 2025 healthcare investor conferences and related webcasts. |
| Nov 06 | Earnings and pipeline | Positive | +1.7% | Q3 2025 results with positive TX45 Phase 1b data and solid cash runway. |
| Oct 29 | Clinical trial data | Positive | -5.5% | Positive TX45 Phase 1b Part B data in Group 2 pulmonary hypertension patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and corporate updates have mostly seen aligned price moves, though some strong clinical news drew negative reactions.
Over the last several months, Tectonic reported multiple milestones, including positive TX45 Phase 1b data and strong cash levels in its Nov 6, 2025 earnings, plus an earlier detailed Phase 1b TX45 readout on Oct 29, 2025. The company has also regularly communicated via investor events and conferences, as seen in the Dec 1, 2025 conference participation release and the Feb 11, 2026 TX2100 KOL event announcement. The current March 2026 conference participation notice continues this pattern of investor-facing updates without introducing new clinical or financial data.
Key Terms
g-protein coupled receptors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026.
| TD Cowen 46th Annual Health Care Conference | |
| Date: | March 4, 2026 |
| Time: | 11:10 AM EST |
| Location: | Boston, MA |
| Format: | Fireside Chat |
| Presenters: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
| Leerink Global Healthcare Conference | |
| Date: | March 11, 2026 |
| Time: | 1:40 PM EST |
| Location: | Miami, FL |
| Format: | Fireside Chat |
| Presenters: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
The live fireside chats can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.
The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their TD Cowen and Leerink representatives to schedule meetings.
About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.
Contacts: Investors: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com Media: Kathryn Morris The Yates Network (914) 204-6412 kathryn@theyatesnetwork.com